Top Tweets for #EconomicMoat

The peptide market: $51 Bn TAM, on its way to $100 Bn by FY34. The pipeline went from ~100 molecules to 800 in development. Semaglutide alone is a $24 Bn drug. But here's the part that matters throughout the value chain A peptide is made on an 8-step assembly line: synthesise the amino acids -> anchor them to a bead -> add one link at a time -> cleave -> purify -> freeze-dry -> fill into a pen. Making the peptide is cheap. Anyone can string amino acids together. The whole moat sits at Step 6: purification. It's slow, it's the hardest capability to build, and it's where the value quietly concentrates. So who captures it? -> Upstream (Aminos Acids): commodity building blocks, thin margins but steady. -> Midstream CDMOs (synthesis + purification): 20-30%+ EBITDA, customer switching takes 2-3 years to re-qualify. This is the sweet spot. -> Downstream (Dr. Reddy's, Sun, Zydus + Shaily's pen-device near-monopoly in India): highest absolute margins, but generics compress them over time. The number to internalise: an FDA-inspected peptide purification line with 3+ commercial programs takes a rival 5+ years and $100M+ to replicate. The largest position is rarely the most durable one. The one that's hardest to copy is. Disclaimer : Not an investment advice.